✦ LIBER ✦

Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study

✍ Scribed by Gelderblom, H.; Blay, J.Y.; Seddon, B.M.; Leahy, M.; Ray-Coquard, I.; Sleijfer, S.; Kerst, J.M.; Rutkowski, P.; Bauer, S.; Ouali, M.; Marreaud, S.; van der Straaten, R.J.H.M.; Guchelaar, H.-J.; Weitman, S.D.; Hogendoorn, P.C.W.; Hohenberger, P.

Book ID: 122119205
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 758 KB
Volume: 50
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2013.10.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Brostallicin, an agent with potential ac

Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

✍ Michael Leahy; Isabelle Ray-Coquard; Jaap Verweij; Axel Le Cesne; Florence Duffa 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 166 KB

Randomised phase II trial of pegylated l

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

✍ I Judson; J.A Radford; M Harris; J.-Y Blay; Q van Hoesel; A le Cesne; A.T van Oo 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 150 KB

Phase II Study of ET-743 in Advanced Sof

Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial

✍ Le Cesne, A. 📂 Article 📅 2005 🏛 American Society of Clinical Oncology 🌐 English ⚖ 196 KB

Performance status is the most powerful

Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcomaThe European Organisation for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study

✍ Penel, N; Glabbeke, M V; Mathoulin-Pelissier, S; Judson, I; Sleijfer, S; Bui, B; 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 356 KB

9403 Eribulin mesylate (E7389) in patien

9403 Eribulin mesylate (E7389) in patients with leiomyosarcoma (LMS) and other (OTH) subtypes of soft tissue sarcoma (STS): a Phase II study from the European Organisation for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC 62052)

✍ Schöffski, P.; Hartmann, J.T.; Hohenberger, P.; Krarup-Hansen, A.; Wanders, J.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Prognostic and predictive factors for ou

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)

✍ Stefan Sleijfer; Monia Ouali; Martine van Glabbeke; Anders Krarup-Hansen; Sjoerd 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 361 KB